Exubera NICE FAD appeal period ends tomorrow
Just a quick update on NICE’s technology appraisal of Exubera, Pfizer’s inhaled insulin. In May, I reported on the draft NICE tech appraisal in an in-depth review. NICE issued their Final Appraisal Determination on October 12th, and the period for appeal ends tomorrow. If Pfizer does not appeal the FAD, it will be used as the basis for a NICE guideline.
This appraisal provides good insight into stringent requirements for cost-effectiveness demonstrations, particularly regarding evidence standards. Whatever you might think of it, this is where evidence-based medicine lives today. If you’re not already familiar with it and you work in the industry, this appraisal is a good opportunity to gain familiarity.
More on this topic
(What's this?)
Dividend Aristocrats in danger
(Dividend Growth Investor, 12/24/08)
Is Pfizer (PFE) a value trap for investors?
(Dividend Growth Investor, 7/21/08)
Global Investing Roundups
(Money Morning, 10/22/08)
